A
Alkermes develops and commercializes medicines for psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders.
COMPASS Pathways
A London-based biotechnology company developing COMP360, an investigational synthetic psilocybin treatment, through a global phase 3 programme in treatment-resistant depression.
COMPASS Pathways is a biotechnology company founded in 2016 and headquartered in London, with offices in New York City. Its stated purpose is to accelerate patient access to evidence-based innovation in mental health, with a focus on serious mental illness. The company operates in the biotechnology, mental health care and pharmaceutical therapeutics sectors.
The company's lead programme is COMP360, an investigational synthetic psilocybin treatment in development for treatment-resistant depression, where it is being studied in a global phase 3 clinical programme. Further research is under way in post-traumatic stress disorder and anorexia nervosa. COMP360 has received FDA Breakthrough Therapy designation and has been accepted into the UK Innovative Licensing and Access Pathway (ILAP), placing the company's work at the intersection of clinical development and evolving regulatory frameworks in both the United States and the United Kingdom.
Development work spans psychedelic-assisted therapy, synthetic psilocybin and late-stage clinical trials. The company was founded out of its co-founders' personal experience with their son's mental health crisis, and describes a mission-driven commitment to finding better treatment options for serious mental illness.
Open jobs
No open jobs right now.